中文 English FOllOW US: logo

Press Release

WuXi AppTec Lab Testing Division’s Bioanalytical Service Unit Passed FDA Inspection

Mar 13, 2017

Mar 01, 2017 Shanghai, Mar.1, 2017—WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's bioequivalence (BE) inspection with no 483 observations. The inspectors from FDA thoroughly audited WuXi’s qualit...

Read More

Lab Testing Division Analytical Service Unit Establishes Extractable and Leachable Testing Service

May 31, 2016

May 31st, 2016, Shanghai – WuXi AppTec Lab Testing Division (LTD) announces its Analytical Service Unit (ASU) has established a new testing service, comprehensive analysis of extractables and leachables substance for medical devices and pharmaceutical packaging materials.   Extractables are chemicals released from a drug packaging/delivery system into an extraction solvent under laboratory condition...

Read More

WuXi AppTec Lab Testing Division announces the opening of its newest animal research facility

May 06, 2016

WuXi AppTec announces the opening of its newest animal research facility located at Laboratory Testing Division’s Center for Animal Research Excellence in Suzhou China. The new Animal Facility is designed to house SPF immune competent and immune deficient rodents in separate barriers located within its 12,000 sq ft professionally designed vivarium. Located next door to WuXi AppTec’s Toxicology facility on Wuzhong Ave.,...

Read More

Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility

Oct 30, 2015

SHANGHAI, Oct. 29, 2015 -- Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products. Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical...

Read More

WuXi PharmaTech Launches Medical Device Testing Services in China

Oct 23, 2015

SHANGHAI, October 23, 2015 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its Laboratory Testing Division (LTD) has launched preclinical medical device testing services in China.  These services are being offered for Chinese and international cl...

Read More

WuXi PharmaTech Launches OncoWuXi, the World’s First Mobile App for Accessing Oncology Services

Oct 12, 2015

WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has launched OncoWuXi, the first App in the world to allow oncology researchers to access oncology models and data on the go. OncoWuXi helps WuXi’s clients anywhere and at any time to identify relevant tumor models ...

Read More

WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee’s Pharm

Aug 26, 2015

SHANGHAI, Aug. 26, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm," Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered in Hong Kong with 20 years of operations in C...

Read More

WuXi AppTec oncology’s 2nd generation online database, the world’s first integrated tumor model online platform “OncoWuXi” is now launched!

May 28, 2015

We are pleased to announce that WuXi AppTec oncology’s 2nd generation online database, the world’s first integrated tumor model online platform “OncoWuXi” is now launched! With recent advancement in whole genome sequencing, Oncology is transforming into a precision medicine era. To capture this opportunity, we have invested great efforts in building OncoWuXi, a comprehensive but user-friendly tumor ...

Read More

SLAS – WuXi AppTec Pre-conference Workshop: Developing an Open Platform for Compound Management and In Vitro Screening

Apr 02, 2015

WuXi AppTec and Society for Laboratory Automation and Screening (SLAS) will co-sponsor a forum on April 8th. This forum will provide a discussion on how to develop an innovative, high quality and efficient platform for compound management and in vitro screening to support the drug discovery process.Speakers from top global pharma as well as Chinese Academia will share their thoughts and experiences on the status and gap analysis of c...

Read More

WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine

Jan 09, 2015

NextCODE and WuXi's Genome Center will offer comprehensive clinical, research, and diagnostic testing products and services worldwide SHANGHAI,Jan. 9, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announces that it has acquired Next...

Read More